Capabilities
Our Digital Health group guides companies through the myriad considerations they encounter as the delivery of healthcare becomes increasingly digital.
As private equity investment in the Life Sciences and Healthcare industry continues to increase, our cohesive regulatory and transactional approach helps ensure success through each phase of investment.
We provide 360-degree support to companies that develop, manufacture and distribute products tailored specifically toward improving women’s health, from start-ups to global corporations.
Our Sunshine and State Law Compliance Group serves as a powerful industry advocate with respect to transparency laws for more than 100 members companies.
We established the Surprise Billing and Price Transparency Group to assist our clients in developing solutions to changes in healthcare transparency laws.
The K&S International Ad Hoc Group is a coalition of 20+ pharma and medical device companies that focuses on international transparency/disclosure laws targeting manufacturers.
January 21, 2026
2025 Year in Review: FDA Drug and Device Advertising and Promotion Enforcement
December 30, 2025
The One Big Beautiful Bill Act Explained: A Detailed Review of Key Changes for the Health Care Industry
December 29, 2025
Medicare and Medicaid Demos Seek to Impose MFN Pricing: An Overview of GENEROUS, GLOBE, and GUARD
January 26, 2026
King & Spalding Welcomes Five-Partner Medicaid Financing and Managed Care Litigation Team
January 9, 2026
John Carroll discusses 2025's biggest antitrust developments and what attorneys should expect in 2026
November 25, 2025
King & Spalding Secures Another Victory for Boehringer Ingelheim in Zantac-Related Trial
October 10, 2025
King & Spalding Secures Significant Victory for R.J. Reynolds